Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis

医学 养生 安全概况 荟萃分析 克拉霉素 随机对照试验 内科学 不利影响 第二线 外科 第一行 幽门螺杆菌
作者
Theodore Rokkas,Konstantinos Ekmektzoglou,Yaron Niv,David Y. Graham
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
卷期号:120 (4): 787-798 被引量:8
标识
DOI:10.14309/ajg.0000000000003084
摘要

INTRODUCTION: In the last few years, numerous new potassium-competitive acid blocker (P-CAB)-based randomized controlled trials (RCTs) concerning the first-line regimens for Helicobacter pylori infection treatment from various countries have been published. However, no network meta-analysis (NWM) exists, which examines the comparative efficacy and safety of P-CAB-based dual, triple, and quadruple treatments, and, therefore, in this NWM, we examined this matter comparing efficacy and safety of these P-CAB-based regimens. METHODS: Databases were searched for identification, screening, eligibility, and inclusion of relevant RCTs. Extracted data were entered into a Bayesian NWM, and the ranking order for each regimen was evaluated by means of the surface under the cumulative ranking area values. RESULTS: Twenty-five eligible RCTs were included with 7,605 patients randomized to 6 first-line regimens, i.e. P-CAB dual therapy, P-CAB triple therapy, P-CAB quadruple therapy, PPI dual therapy, PPI triple therapy, and PPI quadruple therapy. The surface under the cumulative ranking area values (%) for these 6 regimens were 92.7, 62.5, 33.9, 75.1, 19.4, and 16.3, respectively. The comparative effectiveness ranking showed that P-CAB dual therapy regimen ranked first for efficacy and last for adverse effects and had the best profile for integrated efficacy-safety. DISCUSSION: In this NWM concerning the comparative efficacy and safety of P-CAB-based dual, triple, and quadruple regimens for the first-line H. pylori infection treatment, the overall results showed that P-CAB-based dual treatment ranked first for efficacy with the best-integrated efficacy-safety profile. This is of importance, since the dual regimens overcome the crucial issue of clarithromycin resistance. Consequently, these findings are expected to be useful in helping clinical decision making and future guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6应助liujianxin采纳,获得10
刚刚
打打应助liujianxin采纳,获得10
刚刚
1秒前
wmqwmq完成签到,获得积分10
2秒前
orixero应助TTTT采纳,获得30
2秒前
唐禹嘉完成签到 ,获得积分10
2秒前
3秒前
大个应助科研通管家采纳,获得10
3秒前
歪歪发布了新的文献求助10
3秒前
传奇3应助科研通管家采纳,获得10
3秒前
李健应助科研通管家采纳,获得10
3秒前
汉堡包应助科研通管家采纳,获得10
3秒前
nancylan应助科研通管家采纳,获得10
3秒前
认真的灵竹完成签到 ,获得积分10
3秒前
酷波er应助科研通管家采纳,获得10
3秒前
慕青应助科研通管家采纳,获得10
3秒前
充电宝应助科研通管家采纳,获得10
3秒前
Lucas应助科研通管家采纳,获得50
3秒前
嘿嘿应助科研通管家采纳,获得10
3秒前
隐形曼青应助科研通管家采纳,获得10
3秒前
Jared应助科研通管家采纳,获得10
3秒前
大模型应助科研通管家采纳,获得10
3秒前
科研通AI6应助科研通管家采纳,获得10
3秒前
充电宝应助科研通管家采纳,获得10
3秒前
爆米花应助科研通管家采纳,获得10
3秒前
沙心应助科研通管家采纳,获得10
4秒前
思源应助科研通管家采纳,获得10
4秒前
changping应助科研通管家采纳,获得10
4秒前
无极微光应助科研通管家采纳,获得20
4秒前
爆米花应助科研通管家采纳,获得10
4秒前
4秒前
Jared应助科研通管家采纳,获得10
4秒前
小蘑菇应助科研通管家采纳,获得10
4秒前
qingmoheng应助科研通管家采纳,获得10
4秒前
4秒前
爆米花应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
英俊的铭应助科研通管家采纳,获得10
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1581
以液相層析串聯質譜法分析糖漿產品中活性雙羰基化合物 / 吳瑋元[撰] = Analysis of reactive dicarbonyl species in syrup products by LC-MS/MS / Wei-Yuan Wu 1000
Biology of the Reptilia. Volume 21. Morphology I. The Skull and Appendicular Locomotor Apparatus of Lepidosauria 600
The Scope of Slavic Aspect 600
Foregrounding Marking Shift in Sundanese Written Narrative Segments 600
Rousseau, le chemin de ronde 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5539506
求助须知:如何正确求助?哪些是违规求助? 4626266
关于积分的说明 14598554
捐赠科研通 4567151
什么是DOI,文献DOI怎么找? 2503851
邀请新用户注册赠送积分活动 1481627
关于科研通互助平台的介绍 1453241